Drug Trial Radar · NCT04545866
The Budesonide in Babies (BiB) Trial
Last checked: Nov 20, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
642
Actual
Start
Apr 1, 2021
Primary completion
Sep 5, 2024
Study completion Dec 17, 2026
Sponsor
- Lead sponsor
- NICHD Neonatal Research NetworkResearch network
- Sponsor type
- Research network
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- Sep 11, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, up to 48 hours
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3, randomized, masked, active-controlled, multicenter trial designed to determine whether early intratracheal administration of a combination of budesonide with surfactant, as compared to surfactant alone, will reduce the incidence of physiologic bronchopulmonary dysplasia (BPD) or death by 36 weeks' post-menstrual age in extremely preterm infants.
Conditions
- Bronchopulmonary Dysplasia (BPD)
- Respiratory Distress Syndrome
- Prematurity; Extreme
- Neonatal
Interventions
budesonide (Pulmicort nebulizing suspension).Drug
The first dose of budesonide is 0.25 mg/kg in a volume of 1 ml/kg, for a total volume of 2.5 ml/kg of Curosurf + 1 ml/kg of budesonide. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose and 1 ml/kg of budesonide.
surfactant (poractant alfa;Curosurf)Drug
The first dose of surfactant (poractant alfa; Curosurf) is 2.5 ml/kg. If the infant is to receive a second dose of study drug within 50 hours of birth, the dosage of Curosurf is 1.25 ml/kg for the second dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Physiologic BPD or Death by 36 Weeks PMATime frame: Randomization to 36 weeks PMA
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama
Birmingham, Alabama
Stanford University
Palo Alto, California
Sharp Mary Birch Hospital for Women & Newborns
San Diego, California
Emory University
Atlanta, Georgia
Northwestern Lurie Children's Hospital of Chicago
Chicago, Illinois
University of Iowa
Iowa City, Iowa
University of Mississippi Medical Center - Children's of Mississippi
Jackson, Mississippi
University of New Mexico
Albuquerque, New Mexico
University of Rochester
Rochester, New York
RTI International
Durham, North Carolina
Duke University
Durham, North Carolina
Cincinnati Children's Medical Center
Cincinnati, Ohio
Case Western Reserve University, Rainbow Babies and Children's Hospital
Cleveland, Ohio
Research Institute at Nationwide Children's Hospital
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Brown University - Women and Infants Hospital of Rhode Island
Providence, Rhode Island
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas
University of Texas Health Science Center at Houston
Houston, Texas
University of Utah
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.